Loading...
XJPX4978
Market cap62mUSD
Jan 21, Last price  
103.00JPY
1D
0.00%
1Q
-4.63%
Jan 2017
-76.05%
IPO
-97.19%
Name

ReproCell Inc

Chart & Performance

D1W1MN
XJPX:4978 chart
P/E
—
P/S
4.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.59%
Rev. gr., 5y
17.39%
Revenues
2.43b
-17.83%
316,524,000420,077,000460,950,000567,001,0001,066,373,0001,257,812,000926,255,0001,088,527,0001,199,908,0001,286,283,0002,234,568,0002,953,271,0002,426,817,000
Net income
-31m
L-89.71%
-22,206,0005,869,000-133,923,000-451,793,000-1,961,351,000-911,664,000-2,172,046,000-601,424,000-1,016,520,000-812,572,000-575,094,000-305,313,000-31,415,000
CFO
-11m
L-91.85%
-13,076,000-375,000-39,042,000-626,798,000-614,376,000-775,025,000-636,720,000-554,831,000-689,803,000-648,883,000-246,244,000-140,534,000-11,451,000

Profile

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
URL
https://reprocell.co.jp/
IPO date
Jun 26, 2013
Employees
92
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,426,817
-17.83%
2,953,271
32.16%
2,234,568
73.72%
Cost of revenue
2,836,265
3,309,495
2,881,693
Unusual Expense (Income)
NOPBT
(409,448)
(356,224)
(647,125)
NOPBT Margin
Operating Taxes
2,544
1,650
1,361
Tax Rate
NOPAT
(411,992)
(357,874)
(648,486)
Net income
(31,415)
-89.71%
(305,313)
-46.91%
(575,094)
-29.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
538,750
562,872
2,367,064
BB yield
-3.96%
-2.77%
-13.73%
Debt
Debt current
(107,806)
80,000
Long-term debt
Deferred revenue
Other long-term liabilities
8,969
7,754
7,628
Net debt
(7,948,778)
(7,544,220)
(7,150,976)
Cash flow
Cash from operating activities
(11,451)
(140,534)
(246,244)
CAPEX
(192,433)
(161,032)
(48,030)
Cash from investing activities
404,424
(1,087,496)
(2,144,054)
Cash from financing activities
544,050
482,872
2,384,754
FCF
(691,616)
(361,300)
(482,548)
Balance
Cash
6,566,857
6,379,414
4,641,976
Long term investments
1,381,921
1,057,000
2,589,000
Excess cash
7,827,437
7,288,750
7,119,248
Stockholders' equity
1,775,323
1,508,310
964,897
Invested Capital
6,545,241
5,940,212
6,368,091
ROIC
ROCE
EV
Common stock shares outstanding
85,620
84,230
75,949
Price
159.00
-34.02%
241.00
6.17%
227.00
-45.04%
Market cap
13,613,580
-32.94%
20,299,430
17.74%
17,240,423
-41.56%
EV
5,664,802
12,769,035
10,116,114
EBITDA
(372,335)
(307,230)
(587,372)
EV/EBITDA
Interest
80
342
Interest/NOPBT